Impaired fibrinolytic activity in @entity2175 : correlation with urinary albumin excretion and progression of XXXX .

@entity2175 @entity1 @entity8 @entity455 @entity82 @entity2289 @entity6 @entity3916 @entity299 @entity65 @entity2412 @entity1011 @entity3479 @entity413
Progression of @entity8 and @entity65 in @entity6 have been shown to correlate with control of blood @entity413 , lipids, blood pressure, and smoking. These factors, however, do not appear to totally explain these @entity2412 . @entity8 and @entity65 in @entity2175 are associated with @entity455 and @entity82 , both of which may occur with impaired fibrinolysis. A cross-sectional study was therefore performed in 107 type II @entity6 @entity1 recruited from the Denver Metropolitan Area to examine the effect of impaired fibrinolysis, as assessed by the ratio of plasminogen activator inhibitor ( @entity2289 ) to @entity3479 ( @entity3479 ). With urinary albumin excretion (UAE) as a risk factor for both @entity65 , the @entity1 were analyzed with respect to UAE less than and greater than 1 gm/day. The age, blood @entity413 , hemoglobin @entity3916 , duration of @entity6 , lipids, body mass index, and smoking were no different between the groups. As expected, the group with greater UAE had worse renal function, the serum @entity1011 (1.98 +/- 0.24 vs 1.21 +/- 0.05 mg/dl, P < 0.001) and @entity1011 clearance (55.5 +/- 6.0 vs 76.8 +/- 2.7 ml/min, P < 0.001) were significantly different. The type II @entity6 @entity1 with greater UAE exhibited significantly higher @entity2289 / @entity3479 (2.43 +/- 0.26 vs 1.85 +/- 0.07, P < 0.03). The past history of @entity299 was also higher (87.5 vs 72.3%, P < 0.07) in the @entity6 @entity1 with more impaired fibrinolysis and greater UAE. Thus a prospective, randomized clinical trial in @entity2175 with @entity2289 inhibitors is needed.
